Study of new RAS inhibitors for GI solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to be up and about (ECOG 0-1).
- You have advanced pancreatic cancer or colorectal cancer that has spread.
- Your tumor has a specific RAS mutation (G12D for some parts of the study).
- You haven't had major surgery in the last 28 days.
- Your stomach and bowels are working well enough to absorb the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
This trial tests a new drug called GFH276 for people with advanced solid tumors that have a RAS mutation. It aims to see if the drug is safe and effective against these tumors.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.